* Subsequent events: Agreement signed for the acquisition of a portfolio
of
OTC products in Russia

* Interim 2012 dividend of EUR 0.20 per share to be distributed.

The Board of Directors of Recordati S.p.A. approved the
Group's consolidated results for the first nine months 2012
prepared in
accordance with International Accounting Standards and International
Financial
Reporting Standards (IAS/IFRS) and in particular as per IAS 34
requirements for
interim reporting. These financial statements will be available today
at the
company's offices and on the company's website:
http://www.recordati.com/rec_en/investors/reports/
and can also be viewed on the website of Borsa Italiana S.p.A.

Financial highlights

* Consolidated revenue in the first nine months 2012 is EUR 620.3
million, up by
6.8% compared to the same period of the preceding year. International
sales
grow by 11.0%.

* Operating income, at 21.3% of sales, is EUR 132.4 million, an increase
of
2.7% over the same period of the preceding year.

* Net income at 15.0% of sales is EUR 93.1 million, an increase of 1.2%
over the
first nine months of 2011.

* Net financial position* at 30 September 2012 records a net debt of EUR
44.6
million. During the period EUR 21.0 million were paid for the
acquisition of
six OTC products in Germany, EUR 14.3 million overall were paid for the
acquisitions in Poland of the pharmaceutical company Farma-Projekt plus
a
portfolio of products and dividends for a total of EUR 21.3 million
were
distributed. Shareholders' equity increases to EUR 674.9 million.

* Cash and short-term financial investments net of bank overdrafts and
medium/long-term loans which include the measurement at fair value of
hedging
derivatives (fair value hedge).

Business development news

In February the activities for the preparation of a European Phase III
clinical
trial for REC 0482 (NX-1207), following the successful completion
of a
Scientific Advice meeting with the European Medicines Agency (EMA)
were
initiated. The pivotal controlled clinical trial will assess the
efficacy and
safety of a single TRUS-guided intraprostatic injection of the drug in
patients
with lower urinary tract symptoms (LUTS) associated with BPH not
adequately
controlled by medical therapy. A European licensing agreement for
the
development and commercialization of NX-1207 was signed in 2010 by
Recordati and
Nymox Pharmaceutical Corporation. Under the terms of the agreement
Recordati
received exclusive rights to develop and subsequently market and sell the
drug
in Europe including Russia and the CIS, the Middle East, South Africa
and the
Maghreb area of North Africa.

During April the marketing authorizations, the trademarks and additional
assets
concerning six OTC pharmaceuticals for Germany were acquired from Cilag
GmbH
International and McNeil GmbH & Co. oHG. The products acquired are
JHP-Rödler® (mint oil indicated for digestive disorder, headache,
cough and cold), Betadorm®
D (diphenhydramine HCl indicated for sleep disorders),
Rhinopront®
(pseudoephedrine+triprolidine indicated for rhinitis and head colds),
Collomack®
Topical (salicylic acid solution, an anti-corn preparation), Tirgon®
(bisacodyl
for constipation) and Xitix® (vitamin C lozenges to treat vitamin C
deficiency).
Estimated 2012 sales for the six products are of around EUR 6 million.

In August he acquisition of 100% of the share capital of Farma-Projekt
Sp. z
o.o., a Polish pharmaceutical company with headquarters in Krakow,
was
successfully concluded. The value of the transaction (enterprise value)
is of
PLN 71.0 million (approx. EUR 17.4 million) of which PLN 50.8 million
(approx. EUR
12.5 million) were paid at the closing. Of the remaining balance a portion
will
be paid in tranches on future dates and a portion comprises the company's
debt.
Farma-Projekt operates on the Polish pharmaceutical market since
2003 and
markets drugs belonging to a variety of therapeutic areas, mainly
cardiovascular
and urological treatments as well as dietary supplements. The company
employs
around 135 personnel, of which 84 are dedicated to sales and marketing.
Sales in
2011 were of around PLN 47 million (approx. EUR 11.5 million).

Subsequent events and business outlook

In October the agreements covering the acquisition of all rights to five
product
lines on the Russian and CIS market: Alfavit, Qudesan, Vetoron,
Focus and
Carnitone, were signed. The value of the transaction, which will be funded
from
existing liquidity, is of RUB 2.7 billion (approx. EUR 67.2 million). The
closing
of the operation, expected to take place before year-end, is subject to
certain
conditions. The brands of the products acquired, which are OTC
pharmaceuticals
and dietary supplements, are very well known in Russia. Total annual
sales of
the five product lines are of around RUB 1.0 billion (approx. EUR 24.9
million).
Recordati will also enter into cooperation agreements with Akvion
group to
continue manufacturing the acquired products and for commercial
development.

The group's business performance was in line with expectations during
October.
For the full year 2012 we confirm our expectations to achieve revenues
between EUR
810 and EUR 830 million, operating income between EUR 160 and EUR 170
million and net
income between EUR 115 and EUR 120 million.

Further resolutions

The Board of Directors resolved to distribute an interim dividend
relating to
the financial year 2012 amounting to EUR 0.20 (before withholding tax)
on each
outstanding share, excluding shares in treasury stock. The interim dividend
will
be paid, through the authorised intermediaries, as from November 22,
2012 on
coupon No. 10 to be presented on November 19, 2012.

The Independent Auditor's opinion on the distribution of the interim
dividend is
also available at the Company's registered offices as per article
2433-bis of
the Italian Civil Code.

The Directors' Report and financial statements of Recordati S.p.A. as at 30
June
2012, on which the Board of Directors based its resolution to
distribute the
abovementioned interim dividend, are available at the Company's
registered
offices and published on the Company's website (www.recordati.com).
Such
documents may also be viewed on Borsa Italiana S.p.A.'s website.

Conference call

Recordati will be hosting a conference call today 25 October at 4.00 pm
Italian
time (3.00 pm London time, 10.00 am New York time). The dial-in numbers
are:

Italy
+39 02 8058811
toll free 800 213 858

UK
+44 1 212818003
toll free 800 0156384

USA
+1 718 7058794
toll free 855 2656959

France
+33 170918703

Germany
+49 65 255114451

Callers are invited to dial-in 10 minutes before conference time. If
conference
operator assistance is required during the connection please digit *
followed by
0 or call +39 02 8061371. A recording of the conference call will be
placed on
the website www.recordati.com.

A set of slides which will be referred to during the call will be
available on
our website www.recordati.com under Investors/Company Presentations.

Recordati, established in 1926, is a European pharmaceutical group,
listed on
the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM,
ISIN IT
0003828271), with a total staff of over 3,200, dedicated to the
research,
development, manufacturing and marketing of pharmaceuticals.
Headquartered in
Milan, Italy, Recordati has operations in the main European
countries, in
Central and Eastern Europe, and in Turkey. A field force of around
1,700
medical representatives promotes a wide range of innovative
pharmaceuticals,
both proprietary and under license, in a number of therapeutic areas
including a
specialized business dedicated to treatments for rare diseases. Recordati
is a
partner of choice for new product licenses from companies which do not
have a
European presence. Recordati is committed to the research and
development of
new drug entities within the cardiovascular and urogenital therapeutic
areas and
of treatments for rare diseases. Consolidated revenue for 2011 was EUR
762.0
million, operating income was EUR 163.5 million and net income was
EUR 116.4
million.

Statements contained in this release, other than historical facts, are
"forward-looking statements" (as such term is defined in the
Private Securities
Litigation Reform Act of 1995). These statements are based on
currently
available information, on current best estimates, and on assumptions
believed to
be reasonable. This information, these estimates and assumptions may prove
to be
incomplete or erroneous, and involve numerous risks and uncertainties,
beyond
the Company's control. Hence, actual results may differ materially from
those
expressed or implied by such forward-looking statements. All
mentions and
descriptions of Recordati products are intended solely as information
on the
general nature of the company's activities and are not intended to
indicate the
advisability of administering any product in any particular instance.